SBL
ANIP icon

Sargent Bickham Lagudis’s ANI Pharmaceuticals ANIP Stock Holding History

Sargent Bickham Lagudis’s Portfolio ANIP Stock Details ANIP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-13
Closed – – 953
2021
Q3 		$0 Hold
13
– – ﹤0.01% 943
2021
Q2 		$0 Buy
+13
New +$442 ﹤0.01% 924

Other funds holding ANIP

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $33.3B AUM 44.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
FWSM
First Wilshire Securities Management Pasadena, California $486M AUM 50.29% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
GACM
Global Alpha Capital Management Montreal, Quebec, Canada $1.67B AUM 35.09% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return

Sargent Bickham Lagudis's ANIP Position: Q4 2021 in Review

Sargent Bickham Lagudis sold out of ANI Pharmaceuticals (ANIP) in Q4 2021, closing a stake of 13 shares.

Sargent Bickham Lagudis first reported a position in ANIP in Q2 2021 and held it in 2 quarters. The position peaked at $0 in Q3 2021. 132 funds tracked by Wall St. Rank hold ANIP as of Q4 2021.

  • Sargent Bickham Lagudis reported no remaining ANI Pharmaceuticals position as of Q4 2021 after selling out during the quarter.
  • Sargent Bickham Lagudis sold 13 ANI Pharmaceuticals shares in Q4 2021.
  • Sargent Bickham Lagudis first reported a position in ANI Pharmaceuticals in Q2 2021 and held it in 2 quarters.
  • Sargent Bickham Lagudis's ANI Pharmaceuticals position peaked at $0 in Q3 2021.
  • 132 funds tracked by Wall St. Rank held ANI Pharmaceuticals as of Q4 2021.

Based on Sargent Bickham Lagudis's 13F filing for Q4 2021, filed 18 Jan 2022.